Table 1.
Patient and disease characteristics
| Parameter | No. of patients (%) |
|---|---|
| Age at diagnosis, median (range) | 59 (23–86) |
| FIGO stage | |
| I | 27 (24.8) |
| II | 13 (11.9) |
| III | 56 (51.4) |
| IV | 13 (11.9) |
| Pathology | |
| Serous | |
| High grade | 70 (64.2) |
| Low grade | 0 |
| Endometrioid | |
| Grade 3 | 3 (2.8) |
| Grade 2 | 11 (10.1) |
| Grade 1 | 3 (2.8) |
| Clear cell | 17 (15.6) |
| Mucinous, grade 1 | 3 (2.8) |
| Other | 2 (1.8) |
| Cytoreduction | |
| Microscopic | 53 (66.2) |
| 0–1 cm | 13 (16.3) |
| ≥1 cm | 14 (17.5) |
| Missing | 29 |
| Platinum sensitivity | |
| Resistanta) | 25 (23.1) |
| Partially sensitiveb) | 12 (11.1) |
| Sensitivec) | 55 (50.9) |
| No platinum chemotherapy | 16 (14.8) |
| Missing | 1 |
Percentages reflect percentage of total non-missing data.
FIGO, International Federation of Gynecology and Obstetrics; PFI, platinum-free interval.
a)
Resistant: PFI less than 6 months;
b)
Partially sensitive: PFI between 6–12 months;
c)
Sensitive: PFI greater than 12 months.